Assuntos
Ensaios Clínicos Fase III como Assunto , Imagem Molecular/métodos , Pesquisa Translacional Biomédica , Regulamentação Governamental , Humanos , Invenções , Masculino , Medicare/estatística & dados numéricos , Imagem Molecular/economia , Neoplasias da Próstata/diagnóstico por imagem , Cirurgia Assistida por Computador , Estados Unidos , United States Food and Drug AdministrationRESUMO
Effective patient selection before or early during treatment is important to increasing the therapeutic benefits of anticancer treatments. This selection process is often predicated on biomarkers, predominantly biospecimen biomarkers derived from blood or tumour tissue; however, such biomarkers provide limited information about the true extent of disease or about the characteristics of different, potentially heterogeneous tumours present in an individual patient. Molecular imaging can also produce quantitative outputs; such imaging biomarkers can help to fill these knowledge gaps by providing complementary information on tumour characteristics, including heterogeneity and the microenvironment, as well as on pharmacokinetic parameters, drug-target engagement and responses to treatment. This integrative approach could therefore streamline biomarker and drug development, although a range of issues need to be overcome in order to enable a broader use of molecular imaging in clinical trials. In this Perspective article, we outline the multistage process of developing novel molecular imaging biomarkers. We discuss the challenges that have restricted the use of molecular imaging in clinical oncology research to date and outline future opportunities in this area.
Assuntos
Antineoplásicos/uso terapêutico , Biomarcadores Tumorais/metabolismo , Imagem Molecular/métodos , Neoplasias/tratamento farmacológico , Antineoplásicos/economia , Ensaios Clínicos como Assunto , Análise Custo-Benefício , Humanos , Imagem Molecular/economia , Neoplasias/diagnóstico por imagem , Neoplasias/economia , Neoplasias/metabolismo , Seleção de Pacientes , Tomografia por Emissão de Pósitrons/economia , Tomografia por Emissão de Pósitrons/métodos , Microambiente TumoralRESUMO
A highly sensitive, modular three-color fluorescence endomicroscopy imaging platform spanning the visible to near-infrared (NIR) range is demonstrated. Light-emitting diodes (LEDs) were sequentially pulsed along with the camera acquisition to provide up to 20 frames per second (fps) three-color imaging performance or 60 fps single color imaging. The system was characterized for bacterial and cellular molecular imaging in ex vivo human lung tissue and for bacterial and indocyanine green imaging in ex vivo perfused sheep lungs. A practical method to reduce background tissue autofluorescence is also proposed. The platform was clinically translated into six patients with pulmonary disease to delineate healthy, cancerous, and fibrotic tissue autofluorescent structures. The instrument is the most broadband clinical endomicroscopy system developed to date (covering visible to the NIR, 500 to 900 nm) and demonstrates significant potential for future clinical utility due to its low cost and modular capability to suit a wide variety of molecular imaging applications.
Assuntos
Endoscopia , Microscopia de Fluorescência , Imagem Molecular , Idoso , Animais , Broncoscopia , Ensaios Clínicos como Assunto , Endoscopia/economia , Endoscopia/instrumentação , Endoscopia/métodos , Desenho de Equipamento , Feminino , Humanos , Processamento de Imagem Assistida por Computador , Limite de Detecção , Pulmão/diagnóstico por imagem , Masculino , Microscopia de Fluorescência/economia , Microscopia de Fluorescência/instrumentação , Microscopia de Fluorescência/métodos , Pessoa de Meia-Idade , Imagem Molecular/economia , Imagem Molecular/instrumentação , Imagem Molecular/métodos , OvinosRESUMO
INTRODUCTION: Successful breast conserving cancer surgeries come along with tumor free resection margins and account for cosmetic outcome. Positive margins increase the likelihood of tumor recurrence. Intra-operative fluorescence molecular imaging (IFMI) aims to focus surgery on malignant tissue thus substantially lowering the presence of positive margins as compared with standard techniques of breast conservation (ST). A goal of this paper is to assess the incremental number of surgeries and costs of IFMI vs. ST. METHODS: We developed a decision analytical model and applied it for an early evaluation approach. Given uncertainty we considered that IFMI might reduce the proportion of positive margins found by ST from all to none and this proportion is assumed to be reduced to 10% for the base case. Inputs included data from the literature and a range of effect estimates. For the costs of IFMI, respective cost components were added to those of ST. RESULTS: The base case reduction lowered number of surgeries (mean [95% confidence interval]) by 0.22 [0.15; 0.30] and changed costs (mean [95% confidence interval]) by -663 [-1,584; 50]. A tornado diagram identified the Diagnosis Related Group (DRG) costs, the proportion of positive margins of ST, the staff time saving factor and the duration of frozen section analysis (FSA) as important determinants of this cost. CONCLUSIONS: These early results indicate that IFMI may be more effective than ST and through the reduction of positive margins it is possible to save follow-up surgeries-indicating further health risk-and to save costs through this margin reduction and the avoidance of FSA.
Assuntos
Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/cirurgia , Custos de Cuidados de Saúde/estatística & dados numéricos , Margens de Excisão , Mastectomia Segmentar , Imagem Molecular , Imagem Óptica , Cirurgia Assistida por Computador , Benzenossulfonatos/análise , Bevacizumab/análise , Neoplasias da Mama/economia , Neoplasias da Mama/epidemiologia , Ensaios Clínicos Fase I como Assunto/economia , Técnicas de Apoio para a Decisão , Feminino , Corantes Fluorescentes/análise , Secções Congeladas/economia , Alemanha/epidemiologia , Gastos em Saúde/estatística & dados numéricos , Humanos , Indóis/análise , Mastectomia Segmentar/economia , Modelos Teóricos , Imagem Molecular/economia , Duração da Cirurgia , Imagem Óptica/economia , Reoperação/economia , Reoperação/estatística & dados numéricos , Risco , Cirurgia Assistida por Computador/economia , Cirurgia Assistida por Computador/métodosAssuntos
Doença de Alzheimer/terapia , Neoplasias da Mama/terapia , Ensaios Clínicos como Assunto/métodos , Terapias em Estudo/métodos , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/economia , Protocolos de Quimioterapia Combinada Antineoplásica/economia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/diagnóstico , Neoplasias da Mama/economia , Ensaios Clínicos como Assunto/economia , Análise Custo-Benefício/métodos , Feminino , Humanos , Imagem Molecular/economia , Imagem Molecular/métodos , Terapias em Estudo/economiaRESUMO
Tremendous breakthroughs are being made in cancer drug discovery and development. However, such breakthroughs come at a high financial cost. At a time when there is increasing pressure on drug pricing, in part because of increased life expectancy, it is more important than ever to drive new therapeutics towards patients as efficiently as possible. In this review we discuss the applications of molecular imaging in oncology drug development, with a focus on its ability to enable better early decision making, to increase efficiency and thereby to lower costs.
Assuntos
Antineoplásicos , Descoberta de Drogas/métodos , Imagem Molecular/métodos , Antineoplásicos/economia , Antineoplásicos/farmacocinética , Antineoplásicos/farmacologia , Análise Custo-Benefício , Custos de Medicamentos , Descoberta de Drogas/economia , Humanos , Imagem Molecular/economia , Distribuição TecidualRESUMO
OBJECTIVE: The purpose of this study was to examine additional diagnostic workup and costs generated by addition of a single molecular breast imaging (MBI) examination to screening mammography for women with dense breasts. SUBJECTS AND METHODS: Women with mammographically dense breasts presenting for screening mammography underwent adjunct MBI performed with 300 MBq (99m)Tc-sestamibi and a direct-conversion cadmium-zinc-telluride dual-head gamma camera. All subsequent imaging tests and biopsies were tracked for a minimum of 1 year. The positive predictive value of biopsies performed (PPV3), benign biopsy rate, cost per patient screened, and cost per cancer detected were determined. RESULTS: A total of 1651 women enrolled in the study. Among the 1585 participants with complete reference standard, screening mammography alone prompted diagnostic workup of 175 (11.0%) patients and biopsy of 20 (1.3%) and yielded five malignancies (PPV3, 25%). Results of combined screening mammography plus MBI prompted diagnostic workup of 279 patients (17.6%) and biopsy of 67 (4.2%) and yielded 19 malignancies (PPV3, 28.4%). The benign biopsy rates were 0.9% (15 of 1585) for screening mammography alone and 3.0% (48 of 1585) for the combination (p < 0.001). The addition of MBI increased the cost per patient screened from $176 for mammography alone to $571 for the combination. However, cost per cancer detected was lower for the combination ($47,597) than for mammography alone ($55,851). CONCLUSION: The addition of MBI to screening mammography of women with dense breasts increased the overall costs and benign biopsy rate but also increased the cancer detection rate, which resulted in a lower cost per cancer detected than with screening mammography alone.
Assuntos
Neoplasias da Mama/diagnóstico , Neoplasias da Mama/economia , Detecção Precoce de Câncer/economia , Custos de Cuidados de Saúde/estatística & dados numéricos , Mamografia/economia , Imagem Molecular/economia , Tomografia por Emissão de Pósitrons/economia , Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Prevalência , Compostos Radiofarmacêuticos/economia , Tecnécio Tc 99m Sestamibi/economia , Estados Unidos/epidemiologiaRESUMO
OBJECTIVES: The aim of this study was to assess potential cost-effectiveness of using a prostate cancer specific functional imaging technology capable of identifying residual localized disease versus small volume metastatic disease for asymptomatic men with low but detectable prostate specific antigen (PSA) elevation following radical prostatectomy. METHODS: Markov modeling was used to estimate the incremental impact on healthcare system costs (2012 USD) and quality-adjusted life-years (QALYs) of two alternative strategies: (i) using the new diagnostic to guide therapy versus (ii) current usual care-using a combination of computed tomography, magnetic resonance imaging, and bone scan to guide therapy. Costs were based on estimates from literature and Medicare reimbursement. Prostate cancer progression, survival, utilities, and background risk of all-cause mortality were obtained from literature. Base-case diagnostic sensitivity (75 percent), specificity (90 percent), and cost (USD 2,500) were provided by our industry partner GE Healthcare. RESULTS: The new diagnostic strategy provided an average gain of 1.83 (95 percent uncertainty interval [UI]: 1.24-2.64) QALYs with added costs of USD 15,595 (95 percent UI: USD -6,330-44,402) over 35 years. The resulting incremental cost-effectiveness ratio was USD 8,516/QALY (95 percent UI: USD -2,947-22,372). RESULTS were most influenced by the utility discounting rate and test performance characteristics; however, the new diagnostic provided clinical benefits over a wide range of sensitivity and specificity. CONCLUSION: This analysis suggests a diagnostic technology capable of identifying whether men with biochemical recurrence after radical prostatectomy have localized versus metastatic disease would be a cost-effective alternative to current standard work-up. The results support additional investment in development and validation of such a diagnostic.
Assuntos
Imagem Molecular/economia , Neoplasia Residual/diagnóstico por imagem , Neoplasias da Próstata/diagnóstico por imagem , Idoso , Análise Custo-Benefício , Árvores de Decisões , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Econômicos , Metástase Neoplásica/diagnóstico , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/diagnóstico , Anos de Vida Ajustados por Qualidade de Vida , Radiografia , Sensibilidade e Especificidade , Avaliação da Tecnologia BiomédicaRESUMO
Innovative approaches in cancer imaging supported by the National Cancer Institute's $160-million Cancer Imaging Program will give researchers new tools and clinicians better diagnostic and treatment options.